Edinburgh Clinical Trials

ABLE

The "Age of Blood Evaluation" Trial

The "Age of Blood Evaluation" (ABLE)  tested the hypothesis that the transfusion of prestorage leukoreduced RBCs stored for 7 days or less (fresh arm) as compared with standard-issue RBCs stored, on average, 18 to 21 days (control arm) will lead to improved clinical outcomes in the intensive care population.

 

Prof. Lacroix began this study in 2009 in Canada and it extended to the UK, France and the Netherlands. Prof. Walsh was the Chief Investigator in the UK where twenty Intensive Care Units were involved. The Scottish National Blood Transfusion Service, NHS Blood and Transplant and Northern Ireland Blood Transfusion Service provided support for this study.

 
ABLE logo

UK Chief Investigator: Prof. Timothy S. Walsh

Number and location of participating sites (by region/ country): 18 UK sites

NIHR CRN portfolio: 11299
ISR CTN: 44878718
 
Funder: NIHR Health Technology Assessment Board
Start and End date of grant award: 1 September 2011 - 31 July 2016
Start and End date of recruitment: 16 January 2012 - 31 October 2016
 
Current Status: published.
 
Contact Details: Sponsor - University of Edinburgh & NHS Lothian ACCORD

Chief Investigator: Prof T, Walsh, Professor of Critical Care, Edinburgh University, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4TJ

Trial manager: Julia Boyd, Edinburgh Clinical Trials Unit, University of Edinburgh, Outpatients Building - 2nd Floor D36, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU. : 0131 537 3842 or Julia.Boyd@ed.ac.uk

 

ECTU involvement: Trial Management, Database  

(UKCRC)